CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer
Authors:
- 16 October 2017
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 80 (6) , 1105-1112
Abstract
The role of carbohydrate antigen 19-9 (CA19-9) kinetics in patients with biliary tract cancer (BTC) receiving chemotherapy remains to be elucidated.Keywords
This publication has 22 references indexed in Scilit:
- Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancerEuropean Journal of Cancer, 2015
- Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancerBritish Journal of Cancer, 2014
- A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancerCancer Chemotherapy and Pharmacology, 2013
- A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancerCancer Chemotherapy and Pharmacology, 2013
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanBritish Journal of Cancer, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancerCancer Chemotherapy and Pharmacology, 2009
- Prognostic Relevance of Carbohydrate Antigen 19-9 Levels in Patients with Advanced Biliary Tract CancerCancer Epidemiology, Biomarkers & Prevention, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancerAnnals of Oncology, 1996